160 related articles for article (PubMed ID: 30325764)
1. Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
Gossez M; Martin GE; Pace M; Ramjee G; Premraj A; Kaleebu P; Rees H; Inshaw J; Stöhr W; Meyerowitz J; Hopkins E; Jones M; Hurst J; Porter K; Babiker A; Fidler S; Frater J;
AIDS; 2019 Feb; 33(2):185-197. PubMed ID: 30325764
[TBL] [Abstract][Full Text] [Related]
2. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial.
Cotton MF; Violari A; Otwombe K; Panchia R; Dobbels E; Rabie H; Josipovic D; Liberty A; Lazarus E; Innes S; van Rensburg AJ; Pelser W; Truter H; Madhi SA; Handelsman E; Jean-Philippe P; McIntyre JA; Gibb DM; Babiker AG;
Lancet; 2013 Nov; 382(9904):1555-63. PubMed ID: 24209829
[TBL] [Abstract][Full Text] [Related]
3. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.
Calin R; Hamimi C; Lambert-Niclot S; Carcelain G; Bellet J; Assoumou L; Tubiana R; Calvez V; Dudoit Y; Costagliola D; Autran B; Katlama C;
AIDS; 2016 Mar; 30(5):761-9. PubMed ID: 26730568
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
5. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
[TBL] [Abstract][Full Text] [Related]
6. Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.
Easterbrook PJ; Smith M; Mullen J; O'Shea S; Chrystie I; de Ruiter A; Tatt ID; Geretti AM; Zuckerman M
J Int AIDS Soc; 2010 Feb; 13():4. PubMed ID: 20205896
[TBL] [Abstract][Full Text] [Related]
7. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
[TBL] [Abstract][Full Text] [Related]
8. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.
Assoumou L; Weiss L; Piketty C; Burgard M; Melard A; Girard PM; Rouzioux C; Costagliola D;
AIDS; 2015 Sep; 29(15):2003-7. PubMed ID: 26355572
[TBL] [Abstract][Full Text] [Related]
9. Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts.
Hocqueloux L; Avettand-Fènoël V; Jacquot S; Prazuck T; Legac E; Mélard A; Niang M; Mille C; Le Moal G; Viard JP; Rouzioux C;
J Antimicrob Chemother; 2013 May; 68(5):1169-78. PubMed ID: 23335199
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
11. Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.
Papasavvas E; Lada SM; Joseph J; Yin X; Liu Q; Azzoni L; Mounzer K; Kostman JR; Richman D; Montaner LJ
AIDS; 2018 Aug; 32(13):1763-1772. PubMed ID: 30045057
[TBL] [Abstract][Full Text] [Related]
12. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
[TBL] [Abstract][Full Text] [Related]
13. Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.
Clarridge KE; Blazkova J; Einkauf K; Petrone M; Refsland EW; Justement JS; Shi V; Huiting ED; Seamon CA; Lee GQ; Yu XG; Moir S; Sneller MC; Lichterfeld M; Chun TW
PLoS Pathog; 2018 Jan; 14(1):e1006792. PubMed ID: 29324842
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A;
Lancet HIV; 2016 Jan; 3(1):e49-54. PubMed ID: 26762993
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.
Crowell TA; Colby DJ; Pinyakorn S; Sacdalan C; Pagliuzza A; Intasan J; Benjapornpong K; Tangnaree K; Chomchey N; Kroon E; de Souza MS; Tovanabutra S; Rolland M; Eller MA; Paquin-Proulx D; Bolton DL; Tokarev A; Thomas R; Takata H; Trautmann L; Krebs SJ; Modjarrad K; McDermott AB; Bailer RT; Doria-Rose N; Patel B; Gorelick RJ; Fullmer BA; Schuetz A; Grandin PV; O'Connell RJ; Ledgerwood JE; Graham BS; Tressler R; Mascola JR; Chomont N; Michael NL; Robb ML; Phanuphak N; Ananworanich J;
Lancet HIV; 2019 May; 6(5):e297-e306. PubMed ID: 31000477
[TBL] [Abstract][Full Text] [Related]
16. Effect of Pregnancy on Response to Antiretroviral Therapy in HIV-Infected African Women.
Kourtis AP; Wiener J; King CC; Heffron R; Mugo NR; Nanda K; Pyra M; Donnell D; Celum C; Lingappa JR; Baeten JM;
J Acquir Immune Defic Syndr; 2017 Jan; 74(1):38-43. PubMed ID: 27787340
[TBL] [Abstract][Full Text] [Related]
17. Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.
Fidler S; Olson AD; Bucher HC; Fox J; Thornhill J; Morrison C; Muga R; Phillips A; Frater J; Porter K
J Acquir Immune Defic Syndr; 2017 Feb; 74(2):126-133. PubMed ID: 27846036
[TBL] [Abstract][Full Text] [Related]
18. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
19. The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.
Ekwaru JP; Campbell J; Malamba S; Moore DM; Were W; Mermin J
J Int AIDS Soc; 2013 Apr; 16(1):17355. PubMed ID: 23547778
[TBL] [Abstract][Full Text] [Related]
20. Short Communication: Natural killer cells and expression of KIR receptors in chronic HIV type 1-infected patients after different strategies of structured therapy interruption.
Mestre G; Garcia F; Martinez E; Milinkovic A; Lopez A; León A; Mora B; Argelich R; Lozano JM; Peña J; Gatell JM; Plana M
AIDS Res Hum Retroviruses; 2008 Dec; 24(12):1485-95. PubMed ID: 19025397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
